Sundry Photography/iStock Editorial via Getty Images
Johnson & Johnson (NYSE:JNJ) is reportedly suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J’s blockbuster drug Stelara, also known as ustekinumab.
In its suit, J&J (NYSE:JNJ) is seeking a preliminary injunction